XS005 clinical trials
- studies test it
- 6
- open now
- 0
- in phase 3
- 0
- first study started
- 2010
How each study uses XS005 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
6 studies that test it; most in 2010 (2)
| Year | Studies |
|---|---|
| 2010 | 2 |
| 2012 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 3
Dushu Lake Hospital Affiliated to Soochow University (1) · Xspray Pharma AB (1) · Pearl Therapeutics, Inc. (1) · GlaxoSmithKline (1) · Medicines for Malaria Venture (1) · Medical University of South Carolina (1)
Studies
Open first, then newest update. How each study uses XS005 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- XS005 Injection Combined With Stupp Regimen for Adjuvant Chemotherapy in Subjects With Primary Glioblastoma(GBM)Active, not recruitingPhase 1/2Dushu Lake Hospital Affiliated to Soochow UniversityNCT06147505Written as XS005 Injection
- Evaluating the Pharmacokinetic Parameters and Relative Bioavailability of Sorafenib (XS005) in Healthy Male SubjectsCompletedPhase 1Xspray Pharma ABNCT05967377Written as XS005 Sorafenib Tablet A - Period 1
- A Randomized, Open-label, Single-dose, Single-center, Crossover Study in Healthy Subjects to Assess the Relative Bioavailability of PT010CompletedPhase 1Pearl Therapeutics, Inc.NCT03311373Written as Regimen C
- Allogeneic Hematopoietic Stem Cell Transplantation With Reduced Intensity Pre-transplant Conditioning for the Treatment of High-risk Hematological Malignancies (V3)TerminatedPhase 2Medical University of South CarolinaNCT01139164Written as Regimen C
- An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive TumorCompletedPhase 1GlaxoSmithKlineNCT01231568Written as Regimen C
- A Comparison of the Bioavailability of OZ439 When Delivered Directly to the Small Intestine, or Via the Oral RouteCompletedPhase 1Medicines for Malaria VentureNCT01732588Written as 120mg OZ439 caplet via Enterion capsule